All In Biotech

Drug Trial Radar · NCT07206056

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

188

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Nov 9, 2029

Study completion Dec 1, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).

Conditions

  • Progressive Metastatic Castrate Resistant Prostate Cancer

Interventions

  • Tulmimetostat DL1 QDDrug

    Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

  • Tulmimetostat DL2 QDDrug

    Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

  • Tulmimetostat DL3 QDDrug

    Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

  • Tulmimetostat Doses 1 or 2 QDDrug

    Part 1b (dose expansion and optimization): tulmimetostat doses 1 or 2 QD

  • Tulmimetostat RP2D QDDrug

    Part 2: tulmimetostat Recommended Phase 2 Dose (RP2D) QD

  • JSB462 Dose 1 QDDrug

    JSB462 Dose 1 QD

  • JSB462 Dose 2 QDDrug

    JSB462 Dose 2 QD

  • JSB462 QDDrug

    The dose of JSB462 QD will be determined based on the totality of data from Part 1a

  • Standard of Care (SoC)Drug

    Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1a: Dose-limiting toxicities (DLTs)Time frame: Up to 28 days
  2. Part 1a and Part 1b: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
  3. Part 1a and Part 1b: Number of Participants with dose adjustmentsTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
  4. Part 1a and Part 1b: Dose IntensityTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
  5. Part 1a and Part 1b: Duration of exposure to each study drugTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 14 months
  6. Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at Month 6Time frame: Month 6

Locations

35 sites in 14 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute

    Denver, Colorado · Recruiting

  • Sarah Cannon Research Institute

    Jacksonville, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Wichita Urology Group PA

    Wichita, Kansas · Recruiting

  • Mass General Hospital

    Boston, Massachusetts · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Novartis Investigative Site

    Liverpool, Australia · Recruiting

  • Novartis Investigative Site

    St Leonards, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Herlev, Denmark · Recruiting

  • Novartis Investigative Site

    Odense C, Denmark · Recruiting

  • Novartis Investigative Site

    Vejle, Denmark · Recruiting

  • Novartis Investigative Site

    Bordeaux, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Düsseldorf, North Rhine-Westphalia, Germany · Recruiting

  • Novartis Investigative Site

    Jena, Thuringia, Germany · Recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Recruiting

  • Novartis Investigative Site

    Padova, PD, Italy · Recruiting

  • Novartis Investigative Site

    Orbassano, TO, Italy · Recruiting

  • Novartis Investigative Site

    Kuching, Sarawak, Malaysia · Recruiting

  • Novartis Investigative Site

    Tlalpan, Mexico City, Mexico · Recruiting

  • Novartis Investigative Site

    Poznan, Poland · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain · Recruiting

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    London, United Kingdom · Recruiting

  • Novartis Investigative Site

    Sutton, Surrey, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.